Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-8E12 in early Alzheimer's disease
NL-OMON48538Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Dec 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tilavonemab in Alzheimer's disease (AD) (4 arms), sponsored by AbbVie Inc. Primary endpoints: Clinical Dementia Rating - Sum of Boxes and Long-term safety. Started Dec 2018; status: completed.
02
Drugs
tilavonemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON48538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48538.